22 February 2002
Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease.
Iveta Dinne, Uldis Kalnins, Indulis Kumsars, Andrejs Erglis, Sanda JegereMed Sci Monit 2002; 8(2): PI16-20 :: ID: 420922
Abstract
BACKGROUND: According to the literature, the stent thrombosis and restenosisrate after coronary angioplasty (PTCA) can be reduced by using stents covered with biologically activesubstances. The aim of our study was to investigate clinical outcomes of PTCA alone, conventional stainlesssteel stents, and special Tenax stents covered by amorphous silicon carbide (a-SiC: H). Material/Methods:The study involved a retrospective cohort of 300 patients with coronary artery disease who underwentinterventional treatment from 1998 to 2000. One hundred patients received a Tenax stent (BIOTRONIK, Germany)covered by a-SiC: H. For every patient who received a Tenax stent, one patient with non-Tenax stentingand one patient with PTCA without stenting were randomly assigned. RESULTS: In the Tenax group, 1% ofthe patients had an early coronary event due to subacute stent thrombosis, as compared to 2% in the non-Tenaxgroup and 3% in the PTCA group. At 6-month follow-up, the difference in the frequency of major adversecardiac events was more express between the PTCA group and both groups of patients with stents (32% vs.20%; p=0.053; 32% vs. 14%; p=0.002) in comparison with the 30-day and 3-month results. In the non-Tenaxstenting group more events were detected than in the Tenax group (20% vs. 14%; p=0.259), but the differencewas not statistically significant. CONCLUSIONS: The results strongly suggest the protective qualitiesof a-SiC: H stents in reducing early and late coronary events. It can be speculated that Tenax stentsattenuate the progression of endothelial growth at the site of intervention.
Keywords: Angioplasty, Transluminal, Percutaneous Coronary, Carbon Compounds, Inorganic, Cohort Studies, Coronary Arteriosclerosis, Research Support, Non-U.S. Gov, Silicon Compounds, Stents
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952